Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Oncolytics Biotech, Inc’s stock clocked out at $0.61, down -4.59% from its previous closing price of $0.64. In other words, the price has decreased by -$4.59 from its previous closing price. On the day, 0.68 million shares were traded.
Ratios:
To gain a deeper understanding of ONCY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.82 and its Current Ratio is at 2.82. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on October 06, 2022, initiated with a Buy rating and assigned the stock a target price of $3.
On February 17, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.
Stock Price History:
Over the past 52 weeks, ONCY has reached a high of $1.53, while it has fallen to a 52-week low of $0.60. The 50-Day Moving Average of the stock is -21.64%, while the 200-Day Moving Average is calculated to be -36.14%.
Shares Statistics:
A total of 86.42M shares are outstanding, with a floating share count of 84.87M. Insiders hold about 1.80% of the company’s shares, while institutions hold 1.53% stake in the company.
